Skip to main content
. 2016 Nov 23;8(1):705–721. doi: 10.18632/oncotarget.13525

Figure 9. miR-206 increases the severity of DSS-induced colitis.

Figure 9

(A) Bodyweight was reduced in the DSS-treated group from Day 4 onwards; bodyweight reduction was worsened and improved by miR-206 agomir and antagomir administration, respectively. (B) DAI was increased in the DSS-treated group from Day 4 onwards; DAI increase was aggravated and improved by miR-206 agomir and antagomir administration, respectively. (C) DSS treatment resulted in colon shortening in mice, and miR-206-agomir administration caused further shortening. (D) MPO activity was significantly increased in the colon of DSS-treated mice, and was significantly increased and decreased after miR-206 agomir and antagomir treatment, respectively. All data are expressed as means ± SD. **P < 0.01, DSS-treated group versus normal group; #P < 0.05 and ##P < 0.01, DSS+agomir/antagomir group versus corresponding NC group.